Status:
UNKNOWN
D-Serine Treatment For Tardive Dyskinesia
Lead Sponsor:
Herzog Hospital
Conditions:
Schizophrenia and Schizoaffective Disorder
Tardive Dyskinesia
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine si...
Eligibility Criteria
Inclusion
- age 18-70;
- diagnosis of schizophrenia/schizoaffective disorder according to DSM-IV criteria; diagnosis will be made on the basis of SCID interview and information from medical records, previous treating psychiatrists, and family informants;
- history of ≥3 months antipsychotic drugs treatment and present stable dose antipsychotic treatment for at last 4 weeks;
- fulfillment of Schooler-Kane TD research criteria on a first evaluation performed 2-12 weeks prior to study entrance and on a subsequent evaluation performed prior to allocation to experimental treatment.
Exclusion
- meeting criteria for other DSM-IV Axis I diagnoses;
- presence of a neurological disorder or history of significant head injury;
- substance abuse or alcoholism during entire lifetime;
- are judged clinically to be at suicidal or homicidal risk;
- female patients who are pregnant or lactating; female patients who are not pregnant or lactating, if sexually active, must be using medically accepted means of contraception.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2019
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01804920
Start Date
January 1 2013
End Date
January 1 2019
Last Update
October 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herzog Hospital
Jerusalem, Israel